Event

Edward Walsh

MD
University of Rochester

Polina German

PharmD
Gilead Sciences, Inc.

Srinivasa Rao Nama

MD
Gold Coast University Hospital

Robert Jordan

PhD
Gilead Sciences, Inc.

Danielle Porter

PhD
Gilead Sciences, Inc.

Nimrod Maimon

MD
Soroka University Medical Center

David L. Gossage

MD, MBA
Gilead Sciences, Inc.

Jason W. Chien

MD
Gilead Sciences, Inc.

Frederic Riviere

MD
Hôpital d’Instructions des Armées Percy

Anne Bergeron

MD, PhD
Hôpital Saint Louis

Timothy R. Watkins

MD, MSc
Gilead Sciences Inc;Gilead Sciences, Inc.

Ajit P. Limaye

MD
University of Washington

Emilie Catherinot

MD
Foch Hospital;Hôpital Foch

Michael Ison

MD
Northwestern University

Piotr Napora

MD
Centrum Badan Klinicznych

Sung Hwan Jeong

MD
Gachon University Gil Medical Center

Matt McKevitt

PhD
Gilead Sciences, Inc.

Michal Chowers

MD
Meir Medical Center

Harmesh Moudgil

MD
Princess Royal Hospital

David Zeltser

MD
Tel Aviv Sourasky Medical Center

Diane Hanfelt-Goade

M.D.
Tauranga Hospital

Anat Gafter-Gvili

MD
Rabin Medical Center

William Nseir

MD
Nazareth EMMS Hospital

Ying Guo

PhD
Gilead Sciences, Inc.

Francis Couturaud

MD
Centre Hospitalier Régional et Universitaire de Brest

Assy Nimer

MD
Galilee Medical Center

Ann R. Falsey

MD
University of Rochester

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial of Presatovir (GS-5806), a Novel Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Hospitalized Adults